- Abstract:
-
TRIAL DESIGN: HIV-1 vaccine development has advanced slowly due to viral antigenic diversity, poor immunogenicity and recently, safety concerns associated with human adenovirus serotype-5 vectors. To tackle HIV-1 variation, we designed a unique T-cell immunogen HIVconsv from functionally conserved regions of the HIV-1 proteome, which were presented to the immune system using a heterologous prime-boost combination of plasmid DNA, a non-replicating simian (chimpanzee) adenovirus ChAdV-63 and a ...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Publisher's Version
- Publisher:
- Public Library of Science Publisher's website
- Journal:
- PLoS ONE Journal website
- Volume:
- 9
- Issue:
- 7
- Pages:
- e101591
- Publication date:
- 2014-07-09
- Acceptance date:
- 2014-06-04
- DOI:
- EISSN:
-
1932-6203
- URN:
-
uuid:f19e1f0e-c344-45eb-b1e1-213c2bbabc3a
- Source identifiers:
-
475842
- Local pid:
- pubs:475842
- Language:
- English
- Keywords:
- Copyright holder:
- Hayton et al.
- Copyright date:
- 2014
- Notes:
- © 2014 Hayton et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Journal article
Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record